CABTREO FDA approval date

The FDA approved CABTREO on 20 Oct 2023.

FDA approval date
20 Oct 2023

Drug identity has not yet been verified against registry records

Also recorded as ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

Included trials

No linked trials for this drug yet. Browse all trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2023-10-20DayCABTREOFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA216632", "applicant_as_listed_by_fda": "BAUSCH", "brand_names": ["CABTREO"], "active_ingredients": ["ADAPALENE", "BENZOYL PEROXIDE", "CLINDAMYCIN PHOSPHATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20231020", "matched_on": "drug record created from this FDA brand name"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026